Chloroxine API Manufacturers & Suppliers

Chloroxine (CAS number 773-76-2) is a synthetic antibacterial agent classified chemically as a chloroquinoline, characterized by a quinoline core bearing one or more chlorine atoms. It is primarily utilized in topical formulations, notably shampoos, for the management of dandruff and mild to moderately severe seborrheic dermatitis of the scalp.

The clinical indication of chloroxine centers on its efficacy in controlling the symptoms of scalp conditions associated with abnormal scaling and inflammation. These conditions often involve microbial colonization and overgrowth, which chloroxine addresses through its antimicrobial properties.

Pharmacodynamically, chloroxine exhibits inhibitory activity against a range of gram-positive bacteria and certain gram-negative species, as well as antifungal effects against some dermatophytes and yeasts implicated in scalp disorders. Although the precise mechanism of action remains incompletely defined, chloroxine is believed to reduce epidermal mitotic activity, thereby mitigating the excessive scaling characteristic of dandruff and seborrheic dermatitis. Experimental data indicate that chloroxine induces SOS-DNA repair pathways in Escherichia coli, suggesting a potential genotoxic effect on bacterial cells, contributing to its antimicrobial function.

Key pharmacokinetic data for chloroxine are limited, reflecting its primary use in topical administration with minimal systemic absorption. This profile supports a safety margin appropriate for over-the-counter applications in scalp care. Nevertheless, safety considerations should account for local tolerability and hypersensitivity reactions in sensitive individuals. There is limited evidence for significant systemic toxicity due to its topical route of exposure.

Chloroxine is included in several anti-infective and antifungal dermatological products worldwide. It is categorized under anti-bacterial agents and hydroxyquinoline derivatives, reflecting its chemical and therapeutic classification. Approvals for chloroxine-containing formulations vary by regulatory jurisdiction but it is generally accepted for use in dandruff and seborrheic dermatitis management.

For sourcing and quality assurance, manufacturers and procurement specialists should verify chloroxine API identity, purity, and compliance with pharmacopeial or relevant regulatory standards. Analytical characterization should confirm the molecular structure, absence of residual solvents, and limits on impurities to ensure consistent efficacy and safety in finished formulations.